The aim of this program is to compare safety outcomes of patients with 12 week versus 4 week warfarin monitoring as well assess warfarin dosing in patients with a stable warfarin dose.
Dr. Andrew Bomback uses a case vignette to illustrate the work-up of a patient who presents with secondary hypertension in order to differentiate between hypertensive urgency and hypertensive emergency and formulate appropriate interventions.
The American College of Cardiology annual scientific sessions held in Chicago in April 2016 featured a number of late breaking trials that inform cardiovascular prevention in daily practice. The Roundtable will discuss three areas covered in the following trials; HOPE-3 (statins and anti-hypertensive Rx in primary prevention), Gauss-3 (statin intolerance and the LDL-lowering efficacy of the PCSK9inhibitors, ACCELERATE (another HDL raising CETP inhibitor disappoints), and LATITUDE (p38 MAP kinase inhibition in ACS).
In this audio webcast, two recognized cardiologist experts, Dr. James de Lemos and Dr. Benjamin Scirica, will review the management of stable ischemic heart disease (SIHD). Specifically, they will address the following needs: 1) efficient diagnostic testing and assessment of risk in SIHD patients; 2) enhanced quality of life for SIHD patients through more prudent use of antianginal drugs; and 3) improved clinical decision-making regarding when to revascularize SIHD patients.
Dr. Goodman will discuss clinical concerns regarding common thrombotic issues. He will review the causes and the utility of hypercoaguable states. He will discuss the limits of diagnostic testing for idiopathic thrombosis and talk about the treatment options for this condition.
This activity reviews diagnostic and therapeutic approaches for patients with atrial arrhythmias, including supraventricular tachycardia, atrial flutter and atrial fibrillation. Faculty will discuss the safety and efficacy of catheter ablation compared with pharmacologic therapy, as well as recent data on how risk factor modification (hypertension, obesity, exercise, sleep apnea, alcohol) can be used as a means to reduce the recurrence rate for atrial fibrillation.
In this case presentation, Dr. James Underberg, MD, Clinical Assistant Professor of Medicine at NYU School of Medicine & NYU Center for Prevention of Cardiovascular Disease and Director, Bellevue Hospital Lipid Clinic, shares strategies for identifying Heterozygous Familial Hypercholesterolemia (HeFH) in a patient with a lifelong history of elevated cholesterol. He also summarizes data for recently approved PCSK9 inhibitors for treating patients with HeFH.